| Drug Name |
Istradefylline |
| Drug ID |
BADD_D02484 |
| Description |
Istradefylline, or KW6002, was developed by Kyowa Hakko Kirin in Japan for the treatment of Parkinson's disease as an adjunct to standard therapy.[A184067] Unlike standard dopaminergic therapies for Parkinson's, Istradefylline targets adenosine A2A receptors in the basal ganglia.[A184067] This region of the brain is highly involved in motor control.[A184067]
Istradefylline is indicated as an adjunct treatment to [levodopa] and [carbidopa] for Parkinson's disease.[L8237]
This drug was first approved in Japan on 25 March 2013.[A184067] Istradefylline was granted FDA approval on 27 August 2019.[L8213] |
| Indications and Usage |
Istradefylline is indicated in adjunct to levodopa and carbidopa in the treatment of Parkinson's disease.[L8237] |
| Marketing Status |
approved; investigational |
| ATC Code |
N04CX01 |
| DrugBank ID |
DB11757
|
| KEGG ID |
D04641
|
| MeSH ID |
C111599
|
| PubChem ID |
5311037
|
| TTD Drug ID |
D0F4ZY
|
| NDC Product Code |
46016-1550; 12079-2003; 42747-604; 42747-602; 46016-1551 |
| UNII |
2GZ0LIK7T4
|
| Synonyms |
istradefylline | 8-(2-(3,4-dimethoxyphenyl)ethenyl)-1,3-diethyl-3,7-dihydro-7-methyl-1H-purine-2,6-dione | KW 6002 | KW-6002 |
